An interventional study of Injectable in Wrinkle Appearance, Skin Hydration in Healthy Volunteers and Skin Pigmentation, sponsored by Suisselle. Not yet recruiting at 2 sites in France. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Suisselle · Not applicable, Interventional, and Treatment
The current post-market clinical investigation is designed to evaluate the efficacy and safety of Cellbooster Glow (CBG). For this purpose, healthy participants with signs of skin aging in the face will receive a 3-session treatment and will be followed-up over 70 days after the initial injection session. Several objective measurements of skin quality will be performed with different instruments allowing to assess skin wrinkles, elasticity, dryness, pigmentation, roughness, overall inflammation and microcirculation. Subjective clinical improvement will be evaluated, as well as participant and investigator satisfactions. The safety of the injections will be assessed by collecting the Injection Site Reactions (ISRs) and Adverse Events (AEs).
57 studies on the registry are indexed under Pigmentation Disorders; 12 are open to participants now.
This study's planned enrollment of 60 is above the median of 35 across 44 interventional studies indexed under Pigmentation Disorders.
Browse Pigmentation Disorders studies →Suisselle is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In terms of population
Participant having used oral nutritional supplements which may interfere with the study evaluation in the last 3 months (e.g. Omega 3…)
In terms of associated pathology
Participant with coagulation and/or homeostasis disorders.
Relating to previous or ongoing treatment
Participant undergoing a topical (on the face) or systemic treatment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An initial injection session will be performed at visit 2 (D0). A second injection session will be performed at visit 3 (D14). And a third injection session will be performed at visit 4 (D28). CellBooster® Glow (CBG) Class III medical device Composition: * non-crosslinked Sodium Hyaluronate 18 mg * amino acids (Cysteine, Glutathione, Glycine, Lysine, Proline, Valine) * vitamins (Sodium Ascorbyl Phosphate, Biotin) * phosphate buffer pH 6.8-7.6 q.s
Device: Injectable
An initial injection session will be performed at visit 2 (D0). A second injection session will be performed at visit 3 (D14). And a third injection session will be performed at visit 4 (D28).
Change from baseline recorded at visit 1 (Day -7 to Day 0) of epidermis hydration measured with Corneometer® at Day 42.
At each visit, five measurements will be taken on the right cheekbone, a few centimeters below the outer corner of the eye. The recorded value will be the average of the five measurements An improvement of epidermis hydration is defined as an increase higher than 2AU.
Time frame: Day -7 to Day 0 and Day 42.
Change from baseline of epidermis hydration measured with Corneometer® at Day 70.
Time frame: Day 70
Proportion of participants having an improvement with CBG treatment as assessed by the investigator at Day 42 and Day 70, using the GAIS.
An improvement is defined as participant having a score "very much improved", "much improved" or "improved" on the GAIS 5-grade scale: 1. Very much improved 2. Much improved 3. Improved 4. No change 5. Worse
Time frame: Day 42 and Day 70
Degree of satisfaction of the injectors through the answers to a subjective evaluation questionnaire completed for each participant at Day 14.
For each question, the percentage of answers "satisfied" or "very satisfied" will be computed. 5-grade scale 1. :Strongly disagree 2. : Disagree 3. : Neither agree nor disagree 4. : Agree 5. : Strongly agree
Time frame: Day 14
Degree of satisfaction of the participants through the answers to a subjective evaluation questionnaire at Day 42 and Day 70.
For each question, the percentage of participant satisfied, (percentages of answers "agree" or "strongly agree") will be computed. 5-grade scale: Strongly disagree / Disagree / Neither agree nor disagree / Agree / Strongly agree
Time frame: Day 42 and Day 70
Change from baseline of skin elasticity measured with Cutometer® at Day 42 and Day 70.
Time frame: Day 42 and Day 70
Change from baseline of skin microcirculation measured with Laser Doppler at Day 42 and Day 70
Time frame: Day 42 and Day 70
Change from baseline of skin wrinkles measured with fringe projection system at Day 42 and Day 70.
Time frame: Day 42 and Day 70
Change from baseline of skin roughness measured with fringe projection system at Day 42 and Day 70
Time frame: Day 42 and Day 70
Illustration of the aesthetic effect with photos of the whole face (front face and profiles) with Colorface®.
Time frame: Day 0, Day 42 and Day 70
Change from baseline in the skin color and homogeneity
Change from baseline in the skin color and homogeneity (L\*, a\*, b\*, ITA°,IWA, H76) measured with Colorface® at Day 0, Day 42 and Day 70.
Time frame: Day 0, Day 42 and Day 70
Change from baseline in the multi pigment spot measured with Colorface®
Change from baseline in the multi pigment spot measured with Colorface® at Day 0, Day 42 and Day 70.
Time frame: Day 0, Day 42 and Day 70
Change from baseline in the contrast dark circle/ surrounding skin measured with Colorface®
Change from baseline in contrast dark circle/ surrounding skin in deltaL\*, deltaa\*, deltab\*, deltaE76) measured with Colorface® at Day 0, Day 42 and Day 70.
Time frame: Day 0, Day 42 and Day 70
Change from baseline in the pigmented dark circle measured with Colorface®
Change from baseline in the pigmented dark circle (L\*, a\*, b\*, H76) measured with Colorface® at Day 0, Day 42 and Day 70.
Time frame: Day 0, Day 42 and Day 70
Change from baseline in the global redness inflammation (haemoglobin evaluation) measured with Colorface®
Time frame: Day 0, Day 42 and Day 70
Change from baseline in gloss, and specular Gloss(GS)) measured with Colorface®
Change from baseline in gloss (contrast gloss (GC) and specular Gloss(GS)) measured with Colorface® at Day 0, Day 42 and Day 70.
Time frame: Day 0, Day 42 and Day 70.
Evaluation of Injection Site Reactions (ISRs) by the investigator on the face, immediately after each injection session (Day 0, Day 14 and Day 28) and at Day 42 and Day 70.
Time frame: Day 0, Day 14, Day 28, Day 42 and Day 70.
Evaluation of Injection Site Reactions (ISRs) by the participant on the face during 2 weeks after each injection session.
Participant Injection Site Reactions (ISRs) will be tabulated by maximum severity, and duration, after each injection session.
Time frame: Day 0, Day 14, Day 28
Collection of adverse events (AEs) and concomitant treatments during the study.
Time frame: Day 0 to Day 70
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Aug 2027, 6 months later.
Of 21 interventional studies with no phase under Pigmentation Disorders, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 6 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Suisselle